calcium carbonate and alphacalcidol

PreclinicalSmall molecule

calcium carbonate and alphacalcidol is one of 20 small molecule programs targeting Hypoparathyroidism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismActive, not recruiting

HypoparathyroidismPreclinical

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

3 2

Calciferol

Alnylam Pharmaceuticals

Approved

—3

Rocaltrol

Alnylam Pharmaceuticals

Klor-Con

1 5

One-Alpha

Roche

Phase 2

1 6

Forteo

AAlmaject

Phase 2

2 7

Calcium Citrate

CCampus Bio-Medico University

Approved

1 8

Tums

Otsuka

Phase 2

1 9

Rhpth

Takeda

Phase 3

5 10

Transcon Hgh

VVisen Pharmaceuticals (Shanghai) Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoparathyroidism1 trial

Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism

Completed·UUniversity of Athens··NCT04146259·109 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for calcium carbonate and alphacalcidol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — calcium carbonate and alphacalcidol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for calcium carbonate and alphacalcidol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Athens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Athens

calcium carbonate and alphacalcidol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoparathyroidism1 trial

References

Drug Info

Quick Facts

Related News